Search Within

Wassim Abida

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (75)
  2. Journal Article (70)
  3. Editorial (4)
  4. Review (3)
  5. Research Letter (2)
  6. Correspondence (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (156)
  2. Genitourinary Oncology Service (156)
  3. Solid Tumor Oncology Division (156)
  4. GSK Faculty (71)
  5. Human Oncology and Pathogenesis Program (67)
  6. Sloan Kettering Institute Postdocs (58)

More Groups

People
  1. Howard Scher (68)
  2. Michael Morris (38)
  3. David Solit (36)
  4. Nikolaus Schultz (32)
  5. Anuradha Gopalan (31)
  6. Dana Rathkopf (31)

More People

Years
  1. 2025 (6)
  2. 2024 (10)
  3. 2023 (14)
  4. 2022 (15)
  5. 2021 (19)
  6. 2020 (27)

More Years

Publications
  1. Journal of Clinical Oncology (40)
  2. Clinical Cancer Research (15)
  3. Annals of Oncology (13)
  4. Cancer Research (13)
  5. European Urology (8)
  6. JCO Precision Oncology (4)

More Publications

Publishers
  1. American Society of Clinical Oncology (44)
  2. American Association for Cancer Research (31)
  3. Nature Publishing Group (15)
  4. Oxford University Press (13)
  5. Elsevier Science, Inc. (10)
  6. Nature Research (5)

More Publishers

Results (156)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nonoperative management of mismatch repair-deficient tumors
    Journal Article

    Cercek, A.; Foote, M. B.; Rousseau, B.; Smith, J. J.; Shia, J.; Sinopoli, J.; Weiss, J.; Lumish, M.; Temple, L.; Patel, M.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Recent and future developments in the use of poly (ADP-ribose) polymerase inhibitors for prostate cancer
    Review

    Zacchi, F.; Abida, W.; Antonarakis, E. S.; Bryce, A. H.; Castro, E.; Cheng, H. H.; Shandhu, S.; Mateo, J.
    European Urology Oncology (2025)

    Fulltext@MSK | Save
  • A phase 1b/2 study evaluating the activity of tinengotinib in combination with androgen receptor pathway inhibitors (ARPIs) in patients with metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Chen, Y.; McHugh, D. J.; Morris, M. J.; Wu, F.; Peng, P.; Hennessy, K.; Wang, H.; Fan, J.; Zaidi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety
    Meeting Abstract

    Bryce, A. H.; McDermott, R. S.; Piulats, J. M.; Reaume, M. N.; Ostler, P. J.; Gingerich, J. R.; Pintus, E.; Sridhar, S. S.; Bambury, R. M.; Emmenegger, U.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Germline DNA damage repair variants and prognosis of patients with high-risk or metastatic prostate cancer
    Journal Article

    Stopsack, K. H.; Vijai, J.; Conry, M.; Berchuck, J. E.; Kemel, Y.; Vasselman, S. E.; Freeman, D. A.; Lee, G. S. M.; Mandelker, D.; Solit, D. B.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Final clinical and liquid biopsy (LBx) results of phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J. M.; Tagawa, S. T.; Slovin, S.; Sperger, J. M.; Schehr, J. L.; Stahlfeld, C.; Hintz, A. M.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Appleman, L. J.; Taplin, M. E.; Juárez, Á.; Zhang, L.; Chen, Y.; Gupta, N.; Saltzstein, D.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors
    Journal Article

    Chou, J.; Robinson, T. M.; Egusa, E. A.; Lodha, R.; Zhang, M.; Badura, M.; Mikayelyan, M.; Delavan, H. M.; Swinderman, J.; Wilson, C.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • Automated real-world data integration improves cancer outcome prediction
    Journal Article

    Jee, J.; Fong, C.; Pichotta, K.; Tran, T. N.; Luthra, A.; Waters, M.; Fu, C.; Altoe, M.; Liu, S. Y.; Maron, S. B.; more...
    Nature (2024)

    Fulltext@MSK | Save